Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/188881
Title: Effect of sarcopenia on survival of patients with cirrhosis: A meta-analysis
Author: Tantai, Xinxing
Liu, Yi
Yeo, Yee Hui
Praktiknjo, Michael
Mauro, Ezequiel
Hamaguchi, Yuhei
Engelmann, Cornelius
Zhang, Peng
Jeong, Jae Yoon
Van Vugt, Jeroen Laurens Ad
Xiao, Huijuan
Deng, Huan
Gao, Xu
Ye, Qing
Zhang, Jiayuan
Yang, Longbao
Cai, Yaqin
Liu, Yixin
Liu, Na
Li, Zongfang
Han, Tao
Kaido, Toshimi
Sohn, Joo Hyun
Strassburg, Christian
Berg, Thomas
Trebicka, Jonel
Hsu, Yao Chun
IJzermans, Jan Nicolaas Maria
Wang, Jinhai
Su, Grace L.
Ji, Fanpu
Nguyen, Mindie H.
Keywords: Cirrosi hepàtica
Malalties musculars
Hepatic cirrhosis
Muscular Diseases
Issue Date: 14-Nov-2021
Abstract: The association between sarcopenia and prognosis in patients with cirrhosis remains to be determined. In this study, we aimed to quantify the association between sarcopenia and the risk of mortality in patients with cirrhosis, by sex, underlying liver disease etiology, and severity of hepatic dysfunction.PubMed, Web of Science, EMBASE, and major scientific conference sessions were searched without language restriction through 13 January 2021 with additional manual search of bibliographies of relevant articles. Cohort studies of ?100 patients with cirrhosis and ?12 months of follow-up that evaluated the association between sarcopenia, muscle mass and the risk of mortality were included.22 studies with 6965 patients with cirrhosis were included. The pooled prevalence of sarcopenia in patients with cirrhosis was 37.5% overall (95% CI 32.4%-42.8%), higher in male patients, patients with alcohol associated liver disease (ALD), patients with CTP grade C, and when sarcopenia was defined in patients by lumbar 3- skeletal muscle index (L3-SMI). Sarcopenia was associated with the increased risk of mortality in patients with cirrhosis (adjusted-hazard ratio [aHR] 2.30, 95% CI 2.01-2.63), with similar findings in sensitivity analysis of cirrhosis patients without HCC (aHR 2.35, 95% CI 1.95-2.83) and in subgroup analysis by sex, liver disease etiology, and severity of hepatic dysfunction. The association between quantitative muscle mass index and mortality further supports the poor prognosis for patients with sarcopenia (aHR 0.95, 95% CI 0.93-0.98). There was no significant heterogeneity in all analyses.Sarcopenia was highly and independently associated with higher risk of mortality in patients with cirrhosis.The prevalence of sarcopenia and its association with death in patients with cirrhosis remain unclear. This meta-analysis indicated that sarcopenia affected about one-third of patients with cirrhosis and up to 50% in patients with ALD or Child's class C cirrhosis. Sarcopenia was independently associated with about 2-fold higher risk of mortality in patients with cirrhosis. The mortality rate increased with greater severity or longer period of having sarcopenia. Increasing awareness about the importance of sarcopenia in patients with cirrhosis among stakeholders must be prioritized.
Note: Reproducció del document publicat a: https://doi.org/10.1016/j.jhep.2021.11.006
It is part of: Journal of Hepatology, 2021, vol. 76, num. 3, p. 588-599
URI: http://hdl.handle.net/2445/188881
Related resource: https://doi.org/10.1016/j.jhep.2021.11.006
ISSN: 0168-8278
Appears in Collections:Articles publicats en revistes (Institut de Bioenginyeria de Catalunya (IBEC))

Files in This Item:
File Description SizeFormat 
2021_JHep_Effect_NguyenMH.pdf833.9 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons